BCYC News and Press, Bicycle Therapeutics plc From 01/07/20

Cancer Research UK to fund exploratory development of BT7401 through a Phase IIa clinical study Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) tech...

Editor's note: Seeking Alpha is proud to welcome Vince Yeh as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Editor's note: Seeking...

Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will present in a fireside chat at the Piper Jaffr...

After A Shaky Start, the Indexes Continue their Upward Drive Many market commentators suggested that the indexes retreated from strong futures based on the negative chatter coming from the trade talks. I think this is just lazy assumptions. As I have asserted last week, I think ultimatel...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Five IPOs and two SPACs plan to raise $634 million in the week ahead. One of the leading makers of cryptocurrency mining equipment, Canaan (CAN) plans to raise $100 million at a $1.6 billion market cap. It originally filed to raise $400 million (and in 2018 was rumored to be targeting over $...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Arvinas (NASDAQ: ARVN ) initiated with Buy rating and $35 (23% upside) price target at Roth Capital. More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will present at the Jefferies 2019 London Healt...

- BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date - Phase I dose escalation has commenced in the U.S and will be conducted at sites in both the U.S. and UK ...